Cancer – Press Review  – Revue de Presse

Every week on http://marclacroixcancerblog.blogspot.com
Chaque semaine sur http://marclacroixcancerblog.blogspot.com




Press Review (June 1, 2013) – Revue de presse (1 juin 2013)


First-in-class cancer drug approved to fight melanoma
The US Food and Drug Administration (FDA) has approved the first
cancer drug to inhibit a protein — called MEK — that acts in a pathway
that fuels tumour growth. The drug, called Mekinist (trametinib), was
approved on 29 May for use in advanced melanomas with specific
mutations. Other MEK-targeting drugs are being studied in a wide range
of tumours, including lung and thyroid cancers.
By Heidi Ledford. In Nature.com (blog)
http://blogs.nature.com/news/2013/05/first-in-class-cancer-drug-approved-to-fight-melanoma.html

New Possibilities for Prostate Cancer Treatment Revealed
Researchers have identified a sub-group of cells that could contribute
to prostate cancer recurrence, opening up new ways to treat the
disease, which claims more than 3000 lives a year in Australia.
In Science Daily
http://www.sciencedaily.com/releases/2013/05/130529144315.htm

Barbara Brenner, breast cancer awareness advocate, dies at 61
Barbara Brenner, who directed Breast Cancer Action, a San Francisco-
based breast cancer awareness group, for 15 years, died May 10 at her
home in San Francisco. She was 61. Although she $B!H(Bbeat the breast
cancer odds,$B!I(B as she once said, Ms. Brenner resigned her post in 2010
because of amyotrophic lateral sclerosis, a degenerative nerve
disorder known as ALS.
By Valerie J. Nelson. In Washington Post
http://www.washingtonpost.com/local/obituaries/barbara-brenner-breast-cancer-awareness-advocate-dies-at-61/2013/05/29/6ae7758e-c7d5-11e2-8da7-d274bc611a47_story.html

Immunotherapy's cancer remit widens
Combination therapies hold great promise, but at what cost?
By Heidi Ledford. In Nature.com (blog)
http://www.nature.com/news/immunotherapy-s-cancer-remit-widens-1.13079


Cancer de la prostate : le Jevtana bient$(D??(Bt rembours$(D??(B
Marisol Touraine, la ministre de la sant$(D??(B, a annonc$(D??(B, vendredi 31 mai,
le remboursement en France du Jevtana, un traitement co$(D??(Bteux du groupe
Sanofi contre le cancer de la prostate. Interpell$(D??(Be par l'Association
nationale des malades du cancer de la prostate (Anamacap), Mme
Touraine a indiqu$(D??(B sur France Info que le m$(D??(Bdicament serait pris en
charge par l'assurance-maladie.
Dans Le Monde
http://www.lemonde.fr/sante/article/2013/05/31/cancer-de-la-prostate-le-jevtana-bientot-rembourse_3421747_1651302.html

La FDA donne son feu vert $(D??(B 2 nouveaux traitements contre le m$(D??(Blanome
Deux nouvelles th$(D??(Brapies cibl$(D??(Bes du m$(D??(Blanome m$(D??(Btastatique inop$(D??(Brable
ainsi qu'un test diagnostic pour identifier le bon traitement ont re$(D??(Bu
une autorisation de mise sur le march$(D??(B (AMM) de la Food and Drug
Administration (FDA). Les nouveaux agents, le dabrafenib (Tafinalar$(D??(B)
et le trametinib (Mekinist$(D??(B), ont $(D??(Bt$(D??(B d$(D??(Bvelopp$(D??(Bs par GlaxoSmithKline.
Tous deux sont des traitements oraux mais ont des m$(D??(Bcanismes d'action
l$(D??(Bg$(D??(Brement diff$(D??(Brents.
Par Zosia Chustecka, Aude Lecrubier. Dans Medscape
http://www.medscape.fr/oncologie/articles/1545149/








Cancer Blog – Marc Lacroix – Le Blogue du Cancer
http://marclacroixcancerblog.blogspot.com













Marc Lacroix-Corman – InTextoResearch – Baelen  (06/2013)